December 4, 2020 at 5:24 am

The BJGP, a leading primary care research journal, has published an important letter about misdiagnosis of antidepressant dependence and withdrawal. We appreciate the efforts of authors Marion Brown and Stevie Lewis to increase awareness of adverse drug effects that can cause suicidality and suicide.

They write, “Most urgently, we urge individual prescribers to always raise with their patients possibilities such as antidepressant adverse effects and/or potential dose-change and withdrawal issues before initially prescribing an antidepressant for any patient – and before attributing patients’ subsequent development of ‘unexplained’ ‘functional’ symptoms to psychosomatic ‘medically unexplained’ or ‘functional’ syndromes and disorders.”

Read the full article at:

December 1, 2020 at 2:40 pm

MISSD’s Akathisia Campaign Reaches California Commuters

It’s Giving Tuesday, and MISSD wants to give a big shout out to all who help us reduce avoidable suffering and death by increasing akathisia awareness.

Today in San Francisco, commuters and tourists can see our mass transit ads on buses and inside terminals. This ad campaign was made possible by the generosity of supporters dedicated to reducing the 4th leading cause of death: Adverse drug effects.

“Nobody is immune to medication harms, and adverse drug effects don’t discriminate,” said MISSD Founder, Wendy Dolin.

The MISSD Akathisia Awareness Campaign reaches the West Coast. Previous akathisia ads were featured in New York City and Chicago.

Read the article at

November 24, 2020 at 8:55 am

Can IA Reduce Veterans’ Deaths?

“For more than a decade, health officials have watched in vain as suicide rates climbed steadily — by 30 percent nationally since 2000 — and rates in the V.A. system have been higher than in the general population. The trends have defied easy explanation and driven investment in blind analysis: machine learning, or A.I.-assisted algorithms that search medical and other records for patterns historically associated with suicides or attempts in large clinical populations.”

MISSD also hopes the VA will closely examine the role polypharmacy plays in medication-induced suicide among veterans.

Read the full article

November 20, 2020 at 4:18 am

Hair-Loss Drug & Suicidality Side Effects

“Young men using the hair loss drug finasteride, sold under brand-name Propecia, may be at higher risk of experiencing depression, anxiety, and suicidal thoughts,” a new Boston study finds. Researchers identified 356 reports of suicidality, and almost 3,000 reports of other psychological symptoms among men taking finasteride.

Read the full article at

November 19, 2020 at 12:51 pm

Kids at Risk of Polypharmacy Harms

Despite limited evidence of efficacy and mounting safety concerns, “the use of medication from 2 or more psychotropic classes, i.e., polypharmacy, has increased among US youths,” finds a recent study published in JAMA Pediatrics. Polypharmacy increases the risks of serious adverse drug effects, such as akathisia, delirium, and mania, that can cause suicidality.

Get the full story at

October 14, 2020 at 11:06 am

Zoom with MISSD on Oct. 18th

Adverse drug effects, suicidality, addiction, and mental well being are just a few topics to be addressed by Wendy Dolin and other experts by experience from 9 to 11 on October 18th. The program is free and more details are available at

September 29, 2020 at 2:38 pm

A Podcast to Save Lives

“The combination of the inner signs, the outer signs, and the cognitive confusion makes this a very profound, underreported side effect.” –Wendy Dolin, MISSD Founder

Listen to The Divorce and Beyond podcast about akathisia, advocacy, and the tragic loss that led to MISSD.

September 28, 2020 at 6:18 am

Today: MISSD Founder Discusses Akathisia & Advocacy on Popular Podcast

This show “could save your life or the life of someone you love,” says Susan Guthrie, nationally recognized family law attorney, mediator, and host of the popular podcast, “The Divorce and Beyond.” This morning Guthrie talks with MISSD founder, Wendy Dolin, about akathisia and advocacy. The two-part series will also be available on Spotify, iTunes, and similar channels.

Listen at

September 25, 2020 at 7:55 am

Royal College of Psychiatrists Add Akathisia Info

A new publication to help people safely withdraw from antidepressants has been published by the Royal College of Psychiatrists (RCP). The “Antidepressant Withdrawal” leaflet specifically mentions akathisia and suicidal thoughts as symptoms of antidepressant withdrawal. RCP defines akathisia as “a feeling of inner restlessness and inability to stay still (akathisia).”

MISSD presented at the Royal College of Psychiatrists’ (RCP) 2019 International Congress in London. RCP’s then-president said they were developing new akathisia education for its members. MISSD is pleased RCP published the “Antidepressant Withdrawal” leaflet and we hope to soon see RCP’s new akathisia education for prescribers and patients.

To read and share RCP’s Antidepressant Withdrawal leaflet, visit

To view and share MISSD’s RCP presentation, visit

September 24, 2020 at 2:31 pm

FDA Updates Benzo Risk Info

“The current labeling information on the drugs “does not provide adequate warnings about these serious risks and harms associated with these medicines,” the F.D.A.’s announcement said.”

Adverse drug effects associated with benzodiazepine includes akathisia.

Read the full story at